Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -11 | -11 | ||||||
| Net profit | $m | -14 | -19 | -19 | -29 | -17 | -14 | -14 | - |
| EPS reported | $ | -8.62 | -3.84 | ||||||
| Operating cashflow per share | $ | -6.77 | -0.41 | ||||||
| Capex per share | $ | 0.23 | 0.01 | ||||||
| FCF per share | $ | -7.00 | -0.42 | ||||||
| Free cash flow | $m | -11 | -7 | ||||||
| Net debt | $m | 4 | -6 | ||||||
| Book value equity | $m | -10 | 8 | ||||||
| Book value per share | $ | -6.04 | 0.45 | ||||||
| Number of shares | m | 1.62 | 17.12 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.19 | 0.91 | ||||||
| P/S LTM | x | 20.78 | 74.23 | ||||||
| P/FCF LTM | x | -0.16 | -0.98 | ||||||
| EV/EBITDA LTM | x | -0.45 | -0.05 | ||||||
| EV/Sales LTM | x | 65.84 | 7.47 | ||||||
| Earnings Yield LTM | % | -763.13% | -463.11% | ||||||
| FCF Yield | % | -619.72% | -101.53% | ||||||
| Quality | |||||||||
| ROE | % | 142.68% | 952.76% | ||||||
| ROIC | % | -313.55% | -94.78% | ||||||
| Operating margin | % | -11961.4% | -11637.9% | ||||||
| Gross margin | % | -284.09% | -125.26% | ||||||
| FCF/Sales | % | -12880.7% | -7536.8% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -48.24% | -21.49% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.32 | -1.83 | ||||||
| Net Debt/EBITDA | x | -0.31 | 0.46 | ||||||
| EBIT/Net interest | x | -12.96 | -9.72 | ||||||
| Net debt/market cap | % | 204.10% | -89.94% | ||||||
| Net debt/Equity | x | -0.38 | -0.82 | ||||||
| Gross debt/equity | x | -0.50 | 0.51 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free